Skip to content
About CombiGene
Projects
The pain program COZY
The epilepsy project CG01
The lipodystrophy project CGT2
Patent
The Market
Organization
Investors
Financial reports
Prospectus/IM
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association
Company description
IR-contact
Certified Adviser
Media
Press releases
Presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
About CombiGene
Projects
The pain program COZY
The epilepsy project CG01
The lipodystrophy project CGT2
Patent
The Market
Organization
Investors
Financial reports
Prospectus/IM
Financial calendar
Company and share information
Nasdaq First North Growth Market
Corporate governance
Organization
Articles of association
Company description
IR-contact
Certified Adviser
Media
Press releases
Presentations
Ingeneious
Calendar
Contact
Contact us
Downloads
SV
Interim Report January-September 2017
November 1, 2017
The report >>
Share
News
March 13, 2024
CombiGene’s epilepsy project CG01 has been granted patent in two new countries
February 21, 2024
The Danish company Orphazyme has acquired 10% of the shares in CombiGene
February 16, 2024
Year-end report January-December 2023 CombiGene AB (Publ)
February 1, 2024
CombiGene discontinues the preclinical development of the lipodystrophy project CGT2
January 13, 2024
CombiGene has regained the global rights to the epilepsy project CG01
December 20, 2023
Eurostars contributes SEK 8,7 million to the financing of the COZY01 pain project
November 27, 2023
New issue of Ingeneious, no 5 2023
November 10, 2023
Interim report January – September 2023 for CombiGene AB (publ)
Load more